|
|
Vaccine Detail
|
MVvac2-CoV-N |
| Vaccine Information |
- Vaccine Name: MVvac2-CoV-N
- Target Pathogen: MERS-CoV
- Target Disease: Middle East Respiratory Syndrome (MERS)
- Type: Recombinant vector vaccine
- Status: Licensed
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: N protein(Bodmer et al., 2018)
- Immunization Route: Intramuscular injection (i.m.)
- Description: Live-attenuated measles virus (MV) vaccine encoding the MERS-CoV nucleocapsid protein (MERS-N) (Bodmer et al., 2018)
|
| Host Response |
|
Mouse Response
- Host Strain: IFNAR−/−-CD46Ge
- Host age: 6-12 weeks, 7 months (Bodmer et al., 2018)
- Vaccination Protocol: Mice were inoculated intraperitoneally (i.p.) with 1 × 10^5 TCID50 of recombinant virus on days 0 and either on day 21 or 28. (Bodmer et al., 2018)
- Immune Response: Vaccinated animals exhibited high MV virus neutralizing titers (VNT), production of IFN-γ producing cells. (Bodmer et al., 2018)
|
| References |
Bodmer et al., 2018: Bodmer BS, Fiedler AH, Hanauer JRH, Prüfer S, Mühlebach MD. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virology. 2018; 521; 99-9107. [PubMed: 29902727].
|
|
